JP2008536875A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536875A5
JP2008536875A5 JP2008506821A JP2008506821A JP2008536875A5 JP 2008536875 A5 JP2008536875 A5 JP 2008536875A5 JP 2008506821 A JP2008506821 A JP 2008506821A JP 2008506821 A JP2008506821 A JP 2008506821A JP 2008536875 A5 JP2008536875 A5 JP 2008536875A5
Authority
JP
Japan
Prior art keywords
methyl
pharmaceutical composition
bis
optionally substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008506821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/014531 external-priority patent/WO2006113695A1/en
Publication of JP2008536875A publication Critical patent/JP2008536875A/ja
Publication of JP2008536875A5 publication Critical patent/JP2008536875A5/ja
Pending legal-status Critical Current

Links

JP2008506821A 2005-04-15 2006-04-13 ビス(チオヒドラジド)アミド化合物による併用癌療法 Pending JP2008536875A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67213905P 2005-04-15 2005-04-15
PCT/US2006/014531 WO2006113695A1 (en) 2005-04-15 2006-04-13 Combination cancer therapy with bis(thiohydrazide) amide compounds

Publications (2)

Publication Number Publication Date
JP2008536875A JP2008536875A (ja) 2008-09-11
JP2008536875A5 true JP2008536875A5 (OSRAM) 2009-05-28

Family

ID=36694110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506821A Pending JP2008536875A (ja) 2005-04-15 2006-04-13 ビス(チオヒドラジド)アミド化合物による併用癌療法

Country Status (11)

Country Link
US (2) US8017654B2 (OSRAM)
EP (1) EP1877048A1 (OSRAM)
JP (1) JP2008536875A (OSRAM)
AU (1) AU2006236378B2 (OSRAM)
BR (1) BRPI0610219A2 (OSRAM)
CA (1) CA2604907A1 (OSRAM)
IL (1) IL186662A (OSRAM)
MX (1) MX2007012688A (OSRAM)
NZ (1) NZ562572A (OSRAM)
WO (1) WO2006113695A1 (OSRAM)
ZA (1) ZA200708703B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
NZ552159A (en) 2004-06-23 2009-12-24 Synta Pharmaceuticals Corp Bis(thio-hydrazide amide) salts for treatment of cancers
US8148426B2 (en) 2004-11-19 2012-04-03 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
WO2006113493A2 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
EP1877048A1 (en) 2005-04-15 2008-01-16 Synta Pharmaceuticals Corporation Combination cancer therapy with bis(thiohydrazide) amide compounds
CA2607890A1 (en) 2005-05-16 2006-11-23 Synta Pharmaceuticals Corp. Synthesis of bis(thio-hydrazide amide) salts
MX2008002152A (es) 2005-08-16 2008-04-19 Synta Pharmaceuticals Corp Formulacion de bis(tio-hidrazida amida.
EP2061451A2 (en) * 2006-08-21 2009-05-27 Synta Pharmaceuticals Corporation Bis(thiohydrazide amides) for treating melanoma
WO2008024299A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
JP2010501559A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫の再発を予防するまたは遅らせるのに使用するためのビス(チオヒドラジドアミド)
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
TW200826926A (en) * 2006-09-11 2008-07-01 Synta Pharmaceuticals Corp Bis (thiohydrazide amides) formulation
US7645904B2 (en) 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
US8482732B2 (en) * 2007-10-01 2013-07-09 Maskless Lithography, Inc. Alignment system for various materials and material flows
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8633323B2 (en) * 2008-03-31 2014-01-21 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
CN102256937B (zh) 2008-10-22 2014-12-17 辛塔医药品有限公司 双[硫代酰肼酰胺]化合物的过渡金属络合物
KR20110081300A (ko) 2008-10-22 2011-07-13 신타 파마슈티칼스 코프. 비스[티오하이드라자이드 아미드] 화합물의 전이금속 복합물
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
EP2370402A2 (en) 2008-12-01 2011-10-05 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2011069159A2 (en) 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
EP2560627A1 (en) 2010-04-20 2013-02-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide]compounds such as elesclomol for treating cancers
US20140329892A1 (en) * 2011-11-10 2014-11-06 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20150057357A1 (en) 2012-01-05 2015-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH482394A (de) 1966-09-14 1969-12-15 Shell Int Research Herbizides Mittel
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) * 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (OSRAM) 1973-12-17 1975-07-21
US4822777A (en) * 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のn−(場合により置換された)−n′−置換−n,n′−ジ置換ヒドラジン
US4826866A (en) * 1987-11-02 1989-05-02 A. H. Robins Company, Incorporated 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics
DE68904905T2 (de) * 1988-03-09 1993-07-22 Cis Bio Int Herstellung von als radiopharmazeutische produkte verwendbare nitruroverbindungen.
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
AU673057B2 (en) * 1993-02-22 1996-10-24 Abraxis Bioscience, Llc Methods for (in vivo) delivery of biologics and compositionsuseful therefor
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
WO1995013831A1 (en) * 1993-11-17 1995-05-26 The Schepens Eye Research Institute, Inc. Antibody to ocular and vaginal surface epithelium
AU685957B2 (en) 1994-06-03 1998-01-29 Basf Aktiengesellschaft Carbamoyl carboxylic acid hydrazides and their use against fungi
JPH08182050A (ja) 1994-12-27 1996-07-12 Matsushita Electric Works Ltd 無線通信システム
CA2166676C (en) * 1995-01-09 2007-05-01 Yasuhisa Fujibayashi Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative
WO1997011094A1 (en) * 1995-09-22 1997-03-27 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US5739686A (en) * 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US5753200A (en) * 1996-10-07 1998-05-19 Solvay Minerals, Inc. Sodium metabisulfite process
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) * 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6322303B1 (en) * 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) * 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) * 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
JP2004532187A (ja) * 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
US20020198160A1 (en) * 2001-05-01 2002-12-26 Everitt Elizabeth A. Compositions and methods for enhancing the bioavailability of pharmaceutical agents
US20040235813A1 (en) * 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) * 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
EP1405841B1 (en) * 2001-06-20 2006-08-16 Kuraray Co., Ltd. Process for preparation of 2-oxocarboxylic acid esters
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) * 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MXPA04005099A (es) * 2001-11-28 2004-08-19 Sod Conseils Rech Applic Derivados de 5-sulfanil-4h-1,2,4-triazol y su uso como medicamento.
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
DK1611112T3 (da) 2003-02-11 2012-11-19 Cancer Res Inst Isoxazolforbindelser som hæmmere af varmechokproteiner
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 p38/JTV-1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
KR100544347B1 (ko) * 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
EP1730124A4 (en) 2004-03-26 2009-04-01 Amphora Discovery Corp Certain compounds based on triazole, compositions and applications thereof
NZ552159A (en) 2004-06-23 2009-12-24 Synta Pharmaceuticals Corp Bis(thio-hydrazide amide) salts for treatment of cancers
WO2006033913A2 (en) 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US8148426B2 (en) * 2004-11-19 2012-04-03 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
AU2006214164B2 (en) 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
EP1877048A1 (en) 2005-04-15 2008-01-16 Synta Pharmaceuticals Corporation Combination cancer therapy with bis(thiohydrazide) amide compounds
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
JP2008536870A (ja) * 2005-04-15 2008-09-11 シンタ ファーマシューティカルズ コーポレーション 治療のためのナチュラルキラー細胞活性増強法
CA2607890A1 (en) 2005-05-16 2006-11-23 Synta Pharmaceuticals Corp. Synthesis of bis(thio-hydrazide amide) salts
MX2008002152A (es) 2005-08-16 2008-04-19 Synta Pharmaceuticals Corp Formulacion de bis(tio-hidrazida amida.
CA2633438C (en) * 2005-11-18 2012-01-10 Ferox, Inc. Combustion catalyst carriers and methods of using the same
SI22254A (sl) 2006-04-13 2007-10-31 Univerza V Ljubljani Fakulteta Za Farmacijo NOVI ARILSULFONOHIDRAZIDNI INHIBITORJI ENCIMOV MurC IN MurD
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
AU2007288337B2 (en) 2006-08-21 2012-02-16 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
JP2010501559A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫の再発を予防するまたは遅らせるのに使用するためのビス(チオヒドラジドアミド)
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008024299A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
EP2061451A2 (en) 2006-08-21 2009-05-27 Synta Pharmaceuticals Corporation Bis(thiohydrazide amides) for treating melanoma
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
TW200826926A (en) 2006-09-11 2008-07-01 Synta Pharmaceuticals Corp Bis (thiohydrazide amides) formulation
WO2008033449A2 (en) 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
US7645904B2 (en) * 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
CN101616664A (zh) * 2006-11-14 2009-12-30 克塞诺波特公司 加巴喷丁和普加巴林的前药用于治疗耳鸣的应用
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
WO2008136976A2 (en) 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
TW200922550A (en) 2007-08-07 2009-06-01 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
TW200940050A (en) 2007-11-28 2009-10-01 Synta Pharmaceuticals Corp Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide)
WO2009073148A2 (en) 2007-11-28 2009-06-11 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)

Similar Documents

Publication Publication Date Title
JP2008536875A5 (OSRAM)
JP2005524631A5 (OSRAM)
RU2475478C2 (ru) Соединения для лечения пролиферативных расстройств
JP2010501562A5 (OSRAM)
JP2004534846A5 (OSRAM)
JP2012508252A5 (OSRAM)
JP2008520697A5 (OSRAM)
JP2016506916A5 (OSRAM)
JP2013510860A5 (OSRAM)
JP2014528467A5 (OSRAM)
JP2017526677A5 (OSRAM)
JP2011509309A5 (OSRAM)
JP2016040288A5 (OSRAM)
JP2019529518A5 (OSRAM)
JP2008540554A5 (OSRAM)
JP2013532668A5 (OSRAM)
JP2013504536A5 (OSRAM)
JP2014505107A5 (OSRAM)
JP2017511321A5 (OSRAM)
ES2327617T3 (es) Una combinacion que comprende combrestastatina y agentes anticancerosos.
JP2011509301A5 (OSRAM)
JP2009514802A5 (OSRAM)
JP2020502116A5 (OSRAM)
RU2020119562A (ru) Хиназолиноновое соединение и его применение
JP2017533221A5 (OSRAM)